etodolac has been researched along with cyclin d1 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agus, DB; Carson, DA; Corr, M; Fox, W; Hedvat, M; Holden, S; Huang, G; Jain, A; Leoni, LM; Lu, D | 1 |
Anderson, KC; Chauhan, D; Elliott, G; Hamasaki, M; Hideshima, T; Ishitsuka, K; Kanekal, S; Kumar, S; Leoni, LM; Munshi, NC; Podar, K; Raje, N; Roccaro, AM; Shiraishi, N; Tai, YT; Tassone, P; Yasui, H | 1 |
Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N | 1 |
1 trial(s) available for etodolac and cyclin d1
Article | Year |
---|---|
A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
Topics: Administration, Oral; Aged; beta Catenin; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Gene Expression; Humans; Middle Aged; Preoperative Period; Retinoid X Receptor alpha | 2015 |
2 other study(ies) available for etodolac and cyclin d1
Article | Year |
---|---|
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Blotting, Western; CD36 Antigens; Cell Line; Cell Line, Tumor; Coloring Agents; Cyclin D1; Down-Regulation; Enzyme Activation; ErbB Receptors; Etodolac; Flow Cytometry; Humans; Lipid Metabolism; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Models, Chemical; Monocytes; Neoplasm Transplantation; NIH 3T3 Cells; Prostatic Neoplasms; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription Factors; Transcriptional Activation; Transfection | 2004 |
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Caspases; Cell Adhesion; Cell Line, Tumor; Cyclin D1; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Etodolac; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Stereoisomerism | 2005 |